Company: INTS
Filing Date: 2025-04-25
Form Type: 424B4
Source: 0001628280-25-020056
Chunk: 12

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-04-25
Form: 424B4
Chunk 12
---
 not exercised for cash, we will need to raise additional capital in 2025 to complete enrollment and reach data read out for the INVINCIBLE-4 Study. We will retain broad discretion in determining how we will allocate the net proceeds from the sale of Common Stock under this prospectus supplement.                                    |
| Risk Factors                 |     | You should carefully read and consider the information set forth under “Risk Factors,” together with all of the other information set forth in this prospectus, before deciding to invest in our securities.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Nasdaq Capital Market Symbol |     | INTS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

Except as otherwise indicated, the number of shares of Common Stock to be outstanding immediately after this offering is based on 15,264,869 shares of our Common Stock outstanding as of April 24, 2025 and excludes, as of such date, the following: • 2,543,067 shares of Common Stock issuable upon the exercise of outstanding stock options with a weighted average exercise price of $6.18 per share; • 2,041,563 shares of Common Stock issuable upon the exercise of outstanding warrants to purchase Common Stock with a weighted average exercise price of $4.32 per share; and • 2,455,011 additional shares of the Common Stock reserved for future issuance under our equity incentive plans.

<div align='center'>6</div>

Unless otherwise indicated, the discussion and table above assume no exercise of the outstanding options and warrants described above and excludes the shares of Common Stock to be issued upon exercise of the Common Warrants offered in this offering.

<div align='center'>7</div>

### RISK FACTORS
Investing in our securities involves a high degree of risk. You should carefully consider and evaluate all of the information contained in this prospectus and in the documents we incorporate by reference into this prospectus before you decide to purchase our securities. In particular, you should carefully consider and evaluate the risks and uncertainties described under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024. Any of the risks and uncertainties set forth below and in the Annual Report, as updated by annual, quarterly and other reports and documents that we file with the SEC and incorporate by reference into this prospectus, or any prospectus, could materially and adversely affect our business, results of operations and financial condition, which in turn could materially and adversely affect the value of any securities offered